A detailed history of Vanguard Group Inc transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,685,113 shares of KALV stock, worth $19.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,685,113
Previous 1,781,419 5.41%
Holding current value
$19.7 Million
Previous $21.8 Million 8.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$11.07 - $16.04 $1.07 Million - $1.54 Million
-96,306 Reduced 5.41%
1,685,113 $20 Million
Q4 2023

Feb 14, 2024

BUY
$7.58 - $12.25 $370,889 - $599,392
48,930 Added 2.82%
1,781,419 $21.8 Million
Q3 2023

Nov 14, 2023

BUY
$8.95 - $11.35 $1.36 Million - $1.72 Million
151,808 Added 9.6%
1,732,489 $16.7 Million
Q2 2023

Aug 14, 2023

SELL
$7.73 - $10.57 $14,261 - $19,501
-1,845 Reduced 0.12%
1,580,681 $14.2 Million
Q1 2023

May 15, 2023

BUY
$6.3 - $8.39 $2.71 Million - $3.61 Million
429,853 Added 37.29%
1,582,526 $12.4 Million
Q4 2022

Feb 10, 2023

BUY
$4.2 - $14.24 $11,810 - $40,042
2,812 Added 0.24%
1,152,673 $7.79 Million
Q3 2022

Nov 14, 2022

SELL
$9.85 - $16.83 $71,875 - $122,808
-7,297 Reduced 0.63%
1,149,861 $16.7 Million
Q2 2022

Aug 12, 2022

SELL
$8.16 - $15.1 $77,471 - $143,359
-9,494 Reduced 0.81%
1,157,158 $11.4 Million
Q1 2022

May 13, 2022

BUY
$11.2 - $16.97 $315,481 - $478,010
28,168 Added 2.47%
1,166,652 $17.2 Million
Q4 2021

Feb 14, 2022

SELL
$12.36 - $18.28 $596,530 - $882,247
-48,263 Reduced 4.07%
1,138,484 $15.1 Million
Q3 2021

Nov 12, 2021

BUY
$17.11 - $24.49 $3.8 Million - $5.44 Million
222,328 Added 23.05%
1,186,747 $20.7 Million
Q2 2021

Aug 13, 2021

BUY
$23.12 - $29.91 $22.3 Million - $28.8 Million
964,419 New
964,419 $23.1 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $287M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.